Jaramillo S, Krisam J, Le Cornet L, Kratzmann M, Baumann L, Kayser S, Schliemann C, Kaufmann M, Kieser M, Platzbecker U, Müller-Tidow C, Schlenk RF. Multicenter upfront randomized phase II trial of quizartinib and high-dose cytarabine plus mitoxantrone in relapsed/refractory acute myeloid leukemia with FMS-like tyrosine kinase 3 internal tandem duplication. Haematologica; https://doi.org/10.3324/haematol.2025.288362 [Early view].